Update on Licensing and Partnership Agreement
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your CIZ notes
Cizzle Biotechnology, the UK based diagnostics developer, today provides a further update on progress with the Company's planned strategic and exclusive licensing partner in the USA, Cizzle Bio Inc ("BIO").
Following the Company's signing of a memorandum of understanding ("MoU") with BIO announced on 2 April 2024 and the 60 day extension to finalise a full and binding license agreement (the "Agreement") announced on 25 July 2024, the Company has continued to support BIO's plans to market the Company's CIZ1B biomarker and to complete the Agreement. The final details of the Agreement are expected to be completed shortly, at which time the Company will make a further announcement.
In the meantime, BIO continues to attract significant clinical interest to build on the recent collaboration with Moffitt Cancer Center, the number one cancer hospital in Florida and the Southeast USA, to test patients with suspicious lung nodules, as announced on 9 September 2024.
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.